0001654954-18-002886.txt : 20180419 0001654954-18-002886.hdr.sgml : 20180419 20180321163514 ACCESSION NUMBER: 0001654954-18-002886 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1825 K STREET STREET 2: SUITE 510 CITY: WASHINGTON, D.C. STATE: DC ZIP: 33602 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 1825 K STREET STREET 2: SUITE 510 CITY: WASHINGTON, D.C. STATE: DC ZIP: 33602 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 CORRESP 1 filename1.htm Blueprint
 
 
March 21, 2018  
 
 
VIA EDGAR  
 
 
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-3628
 
Attention:
Chris Edwards, Special Counsel
 
Erin Jaskot, Special Counsel
 
Re:
GT Biopharma, Inc.
 
Registration Statement on Form S-3 (File No. 333-223348)
 
Filed March 1, 2018
 
Acceleration Request
 

Ladies and Gentlemen:
 
Pursuant to Rule 461 under the Securities Act of 1933, as amended, GT Biopharma, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement on Form S-3 to 2:00 p.m., Eastern Time, on March 22, 2018, or as soon thereafter as practicable. The Registrant hereby authorizes Jenifer R. Smith of DLA Piper LLP (US), counsel to the Registrant, to orally modify or withdraw this request for acceleration.
 
We request that we be notified of the effectiveness of the Registration Statement by telephone to Jenifer R. Smith of DLA Piper LLP (US) at (512) 457-7037. We also respectfully request that a copy of the Commission’s order declaring the Registration Statement effective be sent to Jenifer R. Smith via facsimile at (512) 721-2212. Thank you for your assistance.
 
Very truly yours,
 
GT BIOPHARMA, INC.
 
By: /s/ Steven Weldon  
Steven Weldon
Chief Financial Officer
 
cc:   Shawn Cross, Chief Executive Officer
        Jenifer R. Smith, DLA Piper LLP (US)